New dopamine pump is “huge step forward” for advanced Parkinson’s

Advances

Author: Parkinson's Life editorsPublished: 9 April 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

DUOPA pump

Campaigners in the US have welcomed the approval of a new dopamine pump as “a huge step forward” for treatment of people with advanced Parkinson’s disease.

Responding to news that the US Food and Drug Administration had approved DUOPA – a portable infusion pump that delivers carbidopa and levodopa directly into the small intestine – NPF national medical director Dr Michael S. Okun said: “The approval of the dopamine pump for the treatment of Parkinson’s disease is a huge step forward for treatment of Parkinson’s disease patients suffering from motor fluctuations and other disabling symptoms.

“We are very enthusiastic about this advance being made available to patients all over the United States.”

NPF is collaborating with AbbVie in the development and delivery of comprehensive training programs for key stakeholders involved in managing treatment with DUOPA.

The pump was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the US.

According to AbbVie, the new treatment is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson’s. In a clinical trial, patients treated with DUOPA reportedly experienced significantly greater reduction in ‘off time’ than patients treated with oral carbidopa-levodopa immediate release tablets.

C. Warren Olanow MD, of the Department of Neurology and Department of Neuroscience, Mount Sinai School of Medicine, and lead investigator of the DUOPA trial, said: “There is an unmet need for treatment options for patients with advanced Parkinson’s disease. As the disease advances, it can be difficult to control motor features.

“In clinical trials, DUOPA was shown to significantly reduce the amount of ‘off’ time people with advanced Parkinson’s disease experienced.”


Go Back

Share this story

Comments


Related articles


Rob_Deering

Agenda

October 2017

Highlights: Shake With Laughter and Tom Isaacs Charity Golf Day

READ MORE
Nudgu lead

Carers' Corner

Now there’s an app to remind your loved ones to take their Parkinson’s meds

Introducing the voice reminder service for Parkinson’s carers

READ MORE
umotif-100-for-parkinsons-app-lead

Special reports

100 for Parkinson’s: patients suffer lower moods, higher stress levels and poorer sleep quality

Latest findings from 100 for Parkinson’s study released

READ MORE